Author: Gangi, Anmol; Mobashwera, Behnaz; Ganczakowski, Mary; Ayto, Robert
Title: Imaging and Hematologic Findings in Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 (AstraZeneca) Vaccination Cord-id: 0aptbc6b Document date: 2021_8_17
ID: 0aptbc6b
Snippet: An earlier incorrect version appeared online. This article was corrected on August 18, 2021. This case series reports six patients (4 men; median age 38 years; interquartile range 26-48) presenting with vaccine-induced thrombocytopenia and thrombosis beginning 3 to 26 days after receiving the first dose of the ChAdOx1 nCoV-19 (AstraZeneca) vaccine. The patients were admitted to a general hospital between 9 to 31 days after the first dose. All patients had strongly detected anti-platelet factor 4
Document: An earlier incorrect version appeared online. This article was corrected on August 18, 2021. This case series reports six patients (4 men; median age 38 years; interquartile range 26-48) presenting with vaccine-induced thrombocytopenia and thrombosis beginning 3 to 26 days after receiving the first dose of the ChAdOx1 nCoV-19 (AstraZeneca) vaccine. The patients were admitted to a general hospital between 9 to 31 days after the first dose. All patients had strongly detected anti-platelet factor 4 antibodies and severe thrombosis. Laboratory features included thrombocytopenia and elevated D-Dimer levels. Thrombotic events were predominantly venous; two patients had arterial or mixed arterial/venous thrombosis. All patients recovered after receiving intravenous immunoglobulin and non-heparin based anticoagulation.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date